+ Watch DNDN
on My Watchlist
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
Dendreon Corporation continues to struggle getting Provenge marketed at a profit. I expect the bleed the last quarter to continue, especially considering the share price increase from $9 to $12 the last few weeks gave it more altitude to drop from.(The $7-$14 in early January also shows the volitility and expectations).The hazards of going it alone in a tough medication market, especially with a drug that is expensive and needs customization. I believe Dendreon could still be a buyout candidate by someone with a better channel already established. This was the intent from the beginning. As such, I don't expect to hold this call very long.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions